Agenus Inc. [NASDAQ: AGEN] stock went on an upward path that rose over 4.35% on Tuesday, amounting to a one-week price decrease of less than -3.36%. The company report on August 9, 2022 that Agenus Provides Corporate Update and Second Quarter 2022 Financial Report.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
Botensilimab (Fc-enhanced CTLA-4)/balstilimab (PD-1) combination data presented at the 2022 ESMO World GI Congress demonstrated remarkable clinical activity in microsatellite stable colorectal cancer (MSS CRC).
Agenus expects to present additional botensilimab expansion cohort data at upcoming conferences in 2022.
Over the last 12 months, AGEN stock dropped by -53.47%. The one-year Agenus Inc. stock forecast points to a potential upside of 69.13. The average equity rating for AGEN stock is currently 1.50, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $786.79 million, with 277.03 million shares outstanding and 230.39 million shares in the current float. Compared to the average trading volume of 5.05M shares, AGEN stock reached a trading volume of 3771411 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Agenus Inc. [AGEN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AGEN shares is $9.33 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AGEN stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Agenus Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 16, 2021. While these analysts kept the previous recommendation, B. Riley FBR raised their target price to Buy. The new note on the price target was released on November 19, 2019, representing the official price target for Agenus Inc. stock. On October 28, 2016, analysts decreased their price target for AGEN shares from 10 to 5.
The Average True Range (ATR) for Agenus Inc. is set at 0.22, with the Price to Sales ratio for AGEN stock in the period of the last 12 months amounting to 2.46. The Price to Book ratio for the last quarter was 288.00, with the Price to Cash per share for the same quarter was set at 0.87.
AGEN Stock Performance Analysis:
Agenus Inc. [AGEN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.36. With this latest performance, AGEN shares gained by 7.46% in over the last four-week period, additionally plugging by 8.68% over the last 6 months – not to mention a drop of -53.47% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AGEN stock in for the last two-week period is set at 57.09, with the RSI for the last a single of trading hit 56.79, and the three-weeks RSI is set at 57.39 for Agenus Inc. [AGEN]. The present Moving Average for the last 50 days of trading for this stock 2.44, while it was recorded at 2.81 for the last single week of trading, and 2.60 for the last 200 days.
Insight into Agenus Inc. Fundamentals:
Agenus Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.80 and a Current Ratio set at 1.80.
Agenus Inc. [AGEN] Insider Position Details
There are presently around $423 million, or 55.80% of AGEN stock, in the hands of institutional investors. The top three institutional holders of AGEN stocks are: STATE STREET CORP with ownership of 23,243,261, which is approximately 30.884% of the company’s market cap and around 10.10% of the total institutional ownership; DEEP TRACK CAPITAL, LP, holding 22,241,417 shares of the stock with an approximate value of $64.06 million in AGEN stocks shares; and VANGUARD GROUP INC, currently with $60.99 million in AGEN stock with ownership of nearly 15.08% of the company’s market capitalization.
81 institutional holders increased their position in Agenus Inc. [NASDAQ:AGEN] by around 32,294,832 shares. Additionally, 78 investors decreased positions by around 20,991,190 shares, while 31 investors held positions by with 93,631,319 shares. The mentioned changes placed institutional holdings at 146,917,341 shares, according to the latest SEC report filing. AGEN stock had 19 new institutional investments in for a total of 4,832,114 shares, while 37 institutional investors sold positions of 2,677,037 shares during the same period.